TWI363629B - Substituted pyrimidodiazepines - Google Patents

Substituted pyrimidodiazepines Download PDF

Info

Publication number
TWI363629B
TWI363629B TW097109660A TW97109660A TWI363629B TW I363629 B TWI363629 B TW I363629B TW 097109660 A TW097109660 A TW 097109660A TW 97109660 A TW97109660 A TW 97109660A TW I363629 B TWI363629 B TW I363629B
Authority
TW
Taiwan
Prior art keywords
mol
tetrahydro
methyl
mixture
racemic
Prior art date
Application number
TW097109660A
Other languages
English (en)
Chinese (zh)
Other versions
TW200843781A (en
Inventor
Jianping Cai
Shaoqing Chen
Xin-Jie Chu
Kang Le
Kin-Chun Thomas Luk
Peter Michael Wovkulich
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39415299&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TWI363629(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of TW200843781A publication Critical patent/TW200843781A/zh
Application granted granted Critical
Publication of TWI363629B publication Critical patent/TWI363629B/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/18Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
TW097109660A 2007-03-22 2008-03-19 Substituted pyrimidodiazepines TWI363629B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US91935807P 2007-03-22 2007-03-22

Publications (2)

Publication Number Publication Date
TW200843781A TW200843781A (en) 2008-11-16
TWI363629B true TWI363629B (en) 2012-05-11

Family

ID=39415299

Family Applications (1)

Application Number Title Priority Date Filing Date
TW097109660A TWI363629B (en) 2007-03-22 2008-03-19 Substituted pyrimidodiazepines

Country Status (23)

Country Link
US (1) US7517873B2 (enExample)
EP (1) EP2139892B1 (enExample)
JP (1) JP5087640B2 (enExample)
KR (1) KR101157848B1 (enExample)
CN (2) CN101636399B (enExample)
AR (1) AR065794A1 (enExample)
AT (1) ATE524472T1 (enExample)
AU (1) AU2008228303B2 (enExample)
BR (1) BRPI0809088A2 (enExample)
CA (1) CA2680757A1 (enExample)
CL (1) CL2008000785A1 (enExample)
CY (1) CY1112102T1 (enExample)
DK (1) DK2139892T3 (enExample)
ES (1) ES2371832T3 (enExample)
HR (1) HRP20110807T1 (enExample)
IL (1) IL200617A (enExample)
MX (1) MX2009010034A (enExample)
PE (1) PE20120495A1 (enExample)
PL (1) PL2139892T3 (enExample)
PT (1) PT2139892E (enExample)
SI (1) SI2139892T1 (enExample)
TW (1) TWI363629B (enExample)
WO (1) WO2008113711A1 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2010001677A (es) * 2007-08-15 2010-03-11 Vertex Pharma Derivados de 4-(9-(3,3-difluorociclopentil)-5,7,7-trimetil-6-oxo-6 ,7,8,9-tetrahidro-5h-pirimido[4,5-b][1,4]diazepin-2-ilamino)-3-me toxibenzamida como inhibidores de las proteinas cinasas humanas plk1 a plk4 para el tratamiento de enfermedades proli
US20110201818A1 (en) 2007-09-25 2011-08-18 Takeda Pharmaceutical Company Limited Polo-like kinase inhibitors
PL2205603T3 (pl) * 2007-09-28 2014-07-31 Cyclacel Ltd Pochodne pirymidyny jako inhibitory kinaz białkowych
US20090291938A1 (en) * 2007-11-19 2009-11-26 Takeda Pharmaceutical Company Limited Polo-like kinase inhibitors
TWI490214B (zh) 2008-05-30 2015-07-01 艾德克 上野股份有限公司 苯或噻吩衍生物及該等作為vap-1抑制劑之用途
EP2303889A1 (en) * 2008-06-18 2011-04-06 F. Hoffmann-La Roche AG Halo-substituted pyrimidodiazepines as plkl inhibitors
BRPI0923305B1 (pt) 2008-12-09 2019-01-22 Gilead Sciences Inc moduladores de receptores toll-like, seu uso e composição farmacêutica que os compreende
CA2748181C (en) 2009-01-06 2019-07-16 Nathanael S. Gray Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders
TWI483941B (zh) 2009-06-17 2015-05-11 Vertex Pharma 流感病毒複製之抑制劑
SI2477987T1 (en) 2009-09-14 2018-03-30 Gilead Sciences, Inc. MODULATORS TO TOLL OF LIKE RECEPTORS
MX2013006836A (es) 2010-12-16 2013-09-26 Vertex Pharma Inhibidores de la replicacion de los virus de la influenza.
UA118010C2 (uk) 2011-08-01 2018-11-12 Вертекс Фармасьютікалз Інкорпорейтед Інгібітори реплікації вірусів грипу
EP2970317A4 (en) 2013-03-15 2016-11-02 Dana Farber Cancer Inst Inc PYRIMIDODIAZEPINONE COMPOUNDS AND METHOD FOR THE TREATMENT OF DISEASES
BR112016001457A2 (pt) 2013-07-25 2017-08-29 Dana Farber Cancer Inst Inc Inibidores de fatores de transcrição e usos dos mesmos
TWI652014B (zh) * 2013-09-13 2019-03-01 美商艾佛艾姆希公司 雜環取代之雙環唑殺蟲劑
SMT201900450T1 (it) 2013-11-13 2019-09-09 Vertex Pharma Inibitori della replicazione di virus dell’influenza
MX2016006200A (es) 2013-11-13 2016-08-08 Vertex Pharma Metodos para preparar inhibidores de la replicacion de virus de influenza.
JP2017504651A (ja) 2014-01-31 2017-02-09 ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド ジアゼパン誘導体の使用
WO2015117053A1 (en) 2014-01-31 2015-08-06 Dana-Farber Cancer Institute, Inc. Diaminopyrimidine benzenesulfone derivatives and uses thereof
ES2930667T3 (es) 2014-07-11 2022-12-21 Gilead Sciences Inc Moduladores de receptores de tipo Toll para el tratamiento de VIH
BR112017002369A2 (pt) 2014-08-08 2017-12-05 Dana Farber Cancer Inst Inc derivados de diazepana e usos dos mesmos
TWI780423B (zh) 2014-09-16 2022-10-11 美商基利科學股份有限公司 類鐸受體調節劑的製備方法
JP2017526730A (ja) 2014-09-16 2017-09-14 ギリアード サイエンシーズ, インコーポレイテッド Toll様受容体モジュレーターの固体形態
WO2016183120A1 (en) 2015-05-13 2016-11-17 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
EP3294717B1 (en) 2015-05-13 2020-07-29 Vertex Pharmaceuticals Inc. Methods of preparing inhibitors of influenza viruses replication
EP3307728A4 (en) 2015-06-12 2019-07-17 Dana Farber Cancer Institute, Inc. COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND CHINESE INHIBITORS
CN108472300A (zh) 2015-09-11 2018-08-31 达纳-法伯癌症研究所股份有限公司 氰基噻吩并三唑并二氮杂环庚三烯及其用途
AU2016319785C1 (en) 2015-09-11 2021-04-01 Dana-Farber Cancer Institute, Inc. Acetamide thienotriazolodiazepines and uses thereof
KR20180081809A (ko) 2015-11-25 2018-07-17 다나-파버 캔서 인스티튜트 인크. 2가 브로모도메인 억제제 및 그의 용도
EP3440084B1 (en) * 2016-04-07 2022-12-21 Dana-Farber Cancer Institute, Inc. Pyrimido-diazepinone kinase scaffold compounds and methods of treating pi3k-mediated disorders
WO2021061894A1 (en) * 2019-09-27 2021-04-01 Dana-Farber Cancer Institute, Inc. Erk5 degraders as therapeutics in cancer and inflammatory diseases
JP7440940B2 (ja) * 2020-03-27 2024-02-29 オップテラ インコーポレイテッド Plk1の選択的分解誘導化合物
WO2022145989A1 (ko) * 2020-12-31 2022-07-07 (주) 업테라 선택적 plk1 억제제로서의 피리미도디아제핀 유도체
IL310678A (en) * 2021-08-10 2024-04-01 Uppthera Inc A new compound that induces PLK1 degradation
GB202313514D0 (en) 2023-09-05 2023-10-18 Cambridge Entpr Ltd Treatment of inflammatory diseases

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE380814T1 (de) * 1999-09-17 2007-12-15 Abbott Gmbh & Co Kg Kinaseinhibitoren als arzneimittel
NZ531928A (en) * 2001-09-04 2005-10-28 Boehringer Ingelheim Pharma Novel dihydropteridinones, method for producing the same and the use thereof as medicaments
CA2652648C (en) * 2006-02-14 2016-10-25 Vertex Pharmaceuticals Incorporated Dihydrodiazepines useful as inhibitors of protein kinases
TW200808325A (en) * 2006-07-06 2008-02-16 Astrazeneca Ab Novel compounds

Also Published As

Publication number Publication date
AR065794A1 (es) 2009-07-01
CL2008000785A1 (es) 2009-03-27
US20080234255A1 (en) 2008-09-25
PT2139892E (pt) 2011-11-21
PE20120495A1 (es) 2012-05-12
US7517873B2 (en) 2009-04-14
PL2139892T3 (pl) 2012-03-30
SI2139892T1 (sl) 2011-12-30
CN101636399B (zh) 2012-04-18
EP2139892B1 (en) 2011-09-14
CY1112102T1 (el) 2015-11-04
HK1139936A1 (en) 2010-09-30
CN102746175B (zh) 2014-01-15
EP2139892A1 (en) 2010-01-06
JP2010521514A (ja) 2010-06-24
WO2008113711A1 (en) 2008-09-25
BRPI0809088A2 (pt) 2014-09-09
CN102746175A (zh) 2012-10-24
ATE524472T1 (de) 2011-09-15
JP5087640B2 (ja) 2012-12-05
KR20090119913A (ko) 2009-11-20
DK2139892T3 (da) 2011-12-12
TW200843781A (en) 2008-11-16
IL200617A (en) 2014-02-27
CA2680757A1 (en) 2008-09-25
ES2371832T3 (es) 2012-01-10
CN101636399A (zh) 2010-01-27
KR101157848B1 (ko) 2012-07-11
IL200617A0 (en) 2010-05-17
AU2008228303A1 (en) 2008-09-25
HRP20110807T1 (hr) 2011-12-31
MX2009010034A (es) 2009-10-12
AU2008228303B2 (en) 2012-04-19

Similar Documents

Publication Publication Date Title
TWI363629B (en) Substituted pyrimidodiazepines
TWI710552B (zh) 作為神經元組織胺受體-3拮抗劑之化合物及其用途
ES2286491T3 (es) Piperidina-ftalazonas sustituidas con pirrolidinadiona, como agentes inhibidores de la pde4.
CN104987324B (zh) 作为alk抑制剂的嘧啶衍生物
JP5609861B2 (ja) キノキサリン化合物
TW202417450A (zh) 三環化合物及其用途
US8318731B2 (en) Pyrrolopyrimidines
TW200918074A (en) Substituted piperidino-dihydrothienopyrimidines
TW201242965A (en) Ring-fused heterocyclic derivative
TW200520758A (en) Novel pharmaceuticals
TW200901994A (en) Spiroindolinone derivatives
TW200908959A (en) Tetrahydropyranochromene gamma secretase inhibitors
EP3768272B1 (en) Jak inhibitors
CN118076586A (zh) Kif18a抑制剂
TWI297270B (en) Substituted n-arylsulfonylheterocyclic amines as gamma-secretase inhibitors
WO2004043959A1 (ja) 新規parp阻害剤
EP3202767A1 (en) Azabicyclo derivatives, process for preparation thereof and medical use thereof
AU2014231722A1 (en) Salts, co-crystals, and polymorphs of an anxiolytic compound
TW201202248A (en) 3,4-dihydropyrrolo[1,2-a]pyrazine-2,8(1H)-dicarboxamide derivatives, preparation thereof and therapeutic use thereof
TW200800194A (en) Kinase inhibitors
WO2023025244A1 (zh) Sarm1酶活性抑制剂及其应用
WO2011136192A1 (ja) イミダゾ[1,2-a]ピリジン誘導体
HK40109178A (zh) 酪氨酸激酶抑制剂
HK40080028B (zh) Tyk2假激酶配体
TW200811131A (en) Piperidine derivatives as CXCR3 receptor antagonists

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees